UGT2B17 and B-cell chronic lymphocytic leukemia: However, our recent findings indicated that UGT2B17 expression also conferred resistance to antileukemic drugs not conjugated by UGT2B17 [10], suggesting that functions independent of the conjugation activity of UGT2B17 are also at play in the context of CLL.